Day: August 6, 2024

AGF Reports July 2024 Assets Under Management and Fee-Earning Assets

TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) — AGF Management Limited reported total assets under management (AUM) and fee-earning assets1 of $49.3 billion as at July 31, 2024.                                             AUM ($ billions) July 31, 2024   June 30, 2024   % Change Month-Over-Month   July 31, 2023   % Change Year-Over-Year   Total Mutual Fund $27.8   $27.2       $24.5       Exchange-traded funds + Separately managed accounts $2.0   $1.9       $1.3       Segregated accounts and Sub-advisory $6.5   $6.4       $7.2       AGF Private Wealth $8.2   $7.9       $7.4       Subtotal (before AGF Capital Partners AUM and fee-earning assets1) $44.5   $43.4       $40.4       AGF Capital Partners $2.7   $2.7       $0.1       Total AUM $47.2   $46.1   2.4%   $40.5   16.5%   AGF Capital Partners fee-earning...

Continue reading

Finning reports Q2 2024 results; delivers record EPS and free cash flow for Q2

VANCOUVER, British Columbia, Aug. 06, 2024 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning”, the “Company”, “we”, “our” or “us”) reported second quarter 2024 results today. All monetary amounts are in Canadian dollars unless otherwise stated. HIGHLIGHTSAll comparisons are to Q2 2023 results unless indicated otherwise. Q2 2024 EPS (1) was $1.02, up 2% from Q2 2023 and a record for Q2. Q2 2024 free cash flow (3) of $330 million was a Q2 record, compared to $31 million in Q2 2023. Net debt to Adjusted EBITDA (1)(2)(4) was 1.8 times at June 30, 2024, compared to 1.7 times at December 31, 2023. Q2 2024 revenue of $2.9 billion and net revenue (2) of $2.6 billion were up 5% and 3%, respectively. Product support revenue was up 0.4% from Q2 2023 and 8% higher compared to Q1 2024. SG&A (1) as a percentage of net...

Continue reading

STERIS Announces Financial Results for Fiscal 2025 First Quarter

Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 billion compared with $1.2 billion in the first quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the first quarter increased 6%. “We are pleased with the start to our new fiscal year and continue to experience positive momentum across each of our segments,” said Dan Carestio, President...

Continue reading

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024. “Having expanded and extended our ASPIRE study to 50 patients and 36 weeks, respectively, to better assess the efficacy and durability of UBX1325 compared to aflibercept, we have been laser-focused on enrollment and execution this quarter,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “I’m pleased to report that due to the excellent performance of our clinical operations team and the enthusiasm and engagement of our investigators, we have not just met, but have exceeded our enrollment goal in this study.” UBX1325 (foselutoclax) is...

Continue reading

Cellectis Provides Financial Results for the Second Quarter 2024

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. “Over the past months, we have achieved a significant milestone with the granting of ODD designations by the Food and Drug Administration and the European Commission, complemented by the FDA’S Rare Pediatric Disease...

Continue reading

Emergent BioSolutions Reports Second Quarter 2024 Financial Results

Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance range Second Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) million Updates FY 2024 guidance GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2024. “In the first half of the year, we made great progress to stabilize our financial position by strategically divesting assets, resolving several legacy issues, and securing operational cash flow and working capital improvements,” said Joe Papa, president and CEO at Emergent. “As a result, we expect to exceed $200 million in debt reduction by the end of the year. With a sharpened focus on our core products, operationalizing a leaner, more flexible footprint with...

Continue reading

Ashland reports financial results1 for third quarter fiscal 2024, issues outlook for fourth quarter and full-year fiscal 2024

Sales of $544 million Net income (including discontinued operations) of $6 million, or $0.12 per diluted share Income from continuing operations of $31 million, or $0.60 per diluted share Adjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted share Adjusted EBITDA of $139 million, up five percent from the prior-year quarter Cash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 million Repurchased 1.3 million shares; $770 million remaining under existing authorization WILMINGTON, Del., Aug. 06, 2024 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) today announced financial results1 for the third quarter of fiscal year 2024, which ended June 30, 2024, and issued its outlook for fourth quarter and full-year fiscal 2024. The global...

Continue reading

Martinrea International Inc. Reports Strong Second Quarter Results and Declares Dividend

TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) — Martinrea International Inc. (TSX : MRE), a diversified and global automotive supplier engaged in the design, development and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, today announced the release of its financial results for the second quarter ended June 30, 2024, and declared a quarterly cash dividend of $0.05 per share. SECOND-QUARTER HIGHLIGHTS Total sales of $1,301.8 million, production sales of $1,263.7 million. Diluted net earnings per share of $0.54 and Adjusted Net Earnings per Share(1) of $0.58. Adjusted Operating Income Margin(1) of 6.3%. Adjusted EBITDA(1) of $166.1 million, a new quarterly record for the Company. Free Cash Flow(1) (excluding principal payments of IFRS-16 lease liabilities) was $51.7 million, a notable improvement...

Continue reading

American Lithium Appoints New CFO

VANCOUVER, British Columbia, Aug. 06, 2024 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | Nasdaq:AMLI | Frankfurt:5LA1) is pleased to announce the appointment of Paul Charlish as Chief Financial Officer (CFO) effective August 1, 2024. Mr. Charlish, most recently served as Vice President Finance and Corporate Secretary of American Lithium, and has over 35 years of financial experience, including audit and tax in public practice, as well as financial reporting and tax for public companies. He has extensive knowledge of financial reporting in accordance with IFRS, risk management, international tax, ICFR/SOX and internal controls, as well as in-depth knowledge of public equity offerings in Canada. During the course of his career, Mr. Charlish has been a key member of successful management...

Continue reading

PTX Metals Comments on Recent Promotional Activity Pursuant to OTC Markets’ Request

TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) — PTX Metals Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“PTX” or the “Company”), a minerals exploration Company with two flagship projects situated in northern Ontario, has received a request from OTC Markets Group Inc. (“OTC Markets”) to issue this statement on recent promotional activity related to the Company’s common shares (the “Common Shares”) traded on the OTCQB market. On July 31, 2024, OTC Markets informed the Company that it became aware of a promotional activity concerning the Company and its Common Shares increased trading on the OTCQB market, including the distribution of one (1) newsletter published by KryptonStreet on behalf of TD Media LLC (“TDM”), discussing the Company, its business, and the general mining industry (“Newsletter”). The...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.